Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease

Citation for published version (APA):

Document status and date:
Published: 01/01/2002

DOI:
10.1183/09031936.02.00762001

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 23 Apr. 2024
Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease


ABSTRACT: The aim of this study was to examine the nature of fibre-type redistribution in relation to fibre metabolic profile in the vastus lateralis in chronic obstructive pulmonary disease (COPD) and COPD subtypes.

Fifteen COPD patients (eight with emphysema stratified by high-resolution computed tomography) and 15 healthy control subjects were studied. A combination of myofibrillar adenosine triphosphatase staining and immunohistochemistry was used to identify pure, as well as hybrid fibre types. For oxidative capacity, fibres were stained for cytochrome c oxidase and succinate dehydrogenase activities, and glycogen phosphorylase for glycolytic capacity.

The proportion of type-I fibres in COPD patients was markedly lower (16% versus 42%), especially in emphysema, and the proportion of hybrid fibres was higher (29% versus 16%) compared to controls. The proportion of fibres staining positive for oxidative enzymes was lower in COPD patients, which correlated with the proportion of type-I fibres. In COPD oxidative capacity was lower within IIA fibres.

The authors conclude that fibre-type transitions are involved in the fibre-type redistribution in chronic obstructive pulmonary disease. Low oxidative capacity is closely related to the proportion of type-I fibres, but an additional reduction of oxidative enzyme activity is present within IIA fibres. Fibre-type abnormalities may be aggravated in emphysema.

hand, the relationship with FEV1 suggests that the loss is more pronounced in patients with severe COPD. In the current study, a further insight into muscular changes in patients with and without emphysema stratified by high-resolution computed tomography (HRCT) is provided.

The aims of this study were: 1) establish whether fibre-type redistribution in COPD occurs through gradual shifts in intracellular MyHC isoform content, which would result in a greater proportion of hybrid fibre types in patients; 2) provide further insight into the behaviour of metabolic enzymes (oxidative and glycolytic) and their relationship to the fibre-type distribution; 3) establish if abnormal fibre-type distribution is aggravated in emphysema patients compared to nonemphysema patients.

Materials and methods

Study population

A group of 15 patients with moderate-to-severe airflow obstruction and 15 healthy age-matched volunteers were studied (table 1). All patients had COPD according to American Thoracic Society (ATS) guidelines [12] and chronic airflow limitation, defined as measured FEV1 <70% of reference FEV1. Patients also had irreversible obstructive airway disease (<10% improvement of FEV1 predicted baseline after β2-agonist inhalation). They were in a clinically stable condition and had not suffered from respiratory tract infection or exacerbation of their clinically stable condition and had not suffered from any other disease (e.g. diabetes, hypertension, heart failure, etc.) for at least 2 weeks prior to the study. Medication usage and doses were retrieved from available hospital files and the referring physician. Patients received standard optimized inhalation treatment. Due to the potentially adverse effects of oral glucocorticoids on skeletal muscle, their influence on the findings in this study was specifically investigated. Doses were expressed as hydrocortisone equivalents day−1. At the time of biopsy seven of the 15 COPD patients were on a maintenance dose of prednisolone (range 5–10 mg·day−1). Exclusion criteria were malignancy, cardiac failure, distal arteriopathy, recent surgery, α1-antiprotease deficiency, severe endocrine, hepatic or renal disorder and use of anticoagulant medication. Written informed consent was obtained from all subjects and the study was approved by the medical ethical committee of the University Hospital Maastricht (Maastricht, the Netherlands).

Pulmonary function tests

All patients and control subjects underwent spirometry to determine, amongst others, FEV1, with the highest value from at least three technically acceptable assessments being used. Residual volume (RV) and intrathoracic gas volume (ITGV) were assessed by whole-body plethysmography and DLCO was measured by using the single-breath method (Masterlab, Jaeger, Wurzburg, Germany). All values obtained were related to a reference value and expressed as percentage of predicted [13].

Assessment of emphysema

Evaluation of the presence of parenchymal destruction, the hallmark of emphysema [14], was performed by HRCT as described previously [15]. The severity and extent of emphysema in each scan were visually scored by two independent observers according to the direct observational method developed by Sakai et al. [16]. HRCT scores ranged from 0 (no emphysema) to 120 (severe emphysema). Patients were stratified by HRCT score into two groups: HRCT score <30: nonemphysema subgroup (Emph−); HRCT score >30: emphysema subgroup (Emph+).

Tissue collection and processing

Arterial oxygen tension (PaO2) was determined (ABL 330; Radiometer, Copenhagen, Denmark) in a blood sample obtained by puncture of the radial artery while breathing room air. Postabsorptive muscle biopsies of the lateral part of the quadriceps femoris were obtained under local anesthesia by the needle biopsy technique [17]. Biopsies were placed in a drop of Tissue-tek® (OCT compound) on a piece of cork with the fibre orientation perpendicular to the plane of the cork. The specimen was frozen in melting isopentane, precooled in liquid nitrogen and stored at −35°C. Serial cryostat cross-sections (10 μm) were made on a cryostat microtome at −20°C and mounted on slides which were stored at −35°C until analysis. Nine consecutive slides (each carrying two or three cross-sections) per biopsy sample were used for fibre-type characterization and enzyme-activity staining. At least 100 (but up to 200) fibres co-existing on all nine slides were numbered and analysed as described previously [18]. Fibres were included if they were part of a cluster of ≥30 fibres and excluded if disturbing

Table 1.—Subject characteristics and lung function data

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Controls</th>
<th>COPD</th>
<th>Emph−</th>
<th>Emph+</th>
</tr>
</thead>
<tbody>
<tr>
<td>(F:M) n</td>
<td>15 (2:13)</td>
<td>15 (3:12)</td>
<td>7 (3:4)</td>
<td>8 (0:8)</td>
</tr>
<tr>
<td>Age yrs</td>
<td>64±4</td>
<td>67±9</td>
<td>64±12</td>
<td>69±4</td>
</tr>
<tr>
<td>BMI kg·m−2</td>
<td>26.7±3.0</td>
<td>23.9±4.0*</td>
<td>25.3±2.8</td>
<td>22.6±4.4</td>
</tr>
<tr>
<td>FEV1 % pred</td>
<td>108±18</td>
<td>42±14***</td>
<td>57±15</td>
<td>32±7**</td>
</tr>
<tr>
<td>PaO2 kPa</td>
<td>11.8±1.7</td>
<td>9.9±1.2**</td>
<td>10.6±1.2</td>
<td>9.2±0.8*</td>
</tr>
<tr>
<td>DLco % pred</td>
<td>121±23</td>
<td>63±24***</td>
<td>84±14</td>
<td>43±8***</td>
</tr>
<tr>
<td>RV % pred</td>
<td>114±25</td>
<td>167±32***</td>
<td>149±22</td>
<td>178±39</td>
</tr>
<tr>
<td>ITGV % pred</td>
<td>107±18</td>
<td>142±22***</td>
<td>125±15</td>
<td>156±22**</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD. BMI: body mass index; DLco: diffusion capacity for carbon monoxide; FEV1: forced expiratory volume in one second; RV: residual volume; ITGV: intrathoracic gas volume; COPD: chronic obstructive pulmonary disease; Emph−: nonemphysema subgroup; Emph+: emphysema subgroup; Significance of difference compared to controls: *: p<0.05, **: p<0.01, ***: p<0.001.
artefacts were present. All staining intensities were analysed by the same person.

**Fibre-type characterization**

The mATPase acidic pre-incubation was performed at pH 4.4 [19] and the mATPase alkali pre-incubation was performed at pH 10.4 [20]. The double pre-incubation method was performed at pH 10.4 and pH 4.6 [21], the only difference being that the fixation of sections was performed prior to the alkaline pre-incubation. After pre-incubation, sections were stained and mounted [22]. Figure 1a–c show examples of mATPase staining.

Immunohistochemistry was performed with a panel of monoclonal antibodies (MAbs); anti-type I MyHC (MAb 219-1D1), anti-type IIA MyHC (MAb 333-7H1), anti-types IIA+IIX MyHC (MAb 332-3D4) [23]. Figure 1d–f show examples of MyHC staining.

Fibres were assigned to categories, first on the basis

---

**Fig. 1.** – Examples of histochemical analysis in nine consecutive cross-sections. Myofibrillar adenosine triphosphatase (mATPase) staining with: a) acidic, b) alkaline and c) double pre-incubation (positive fibres stain dark); immunohistochemistry with: d) anti-type I, e) anti-type IIA and f) anti-types IIA+IIX (positive fibres stain dark). Fibres numbered 1–5 are assigned to the I, IIA, IIA+IIX and IIX combination of mATPase and myosin heavy chain fibre type categories, respectively (staining intensities are given in table 2). g) Cytochrome c oxidase activity staining (positive fibres are coloured brown). h) Succinate dehydrogenase activity (positive fibres are coloured blue). i) Glycogen phosphorylase positive fibres are coloured purple and negative fibres yellow. Internal scale bars=150 μm.
of three mATPase staining intensities (-, + or ++) and secondly by immunoreactivity (- or ++) (table 2). The following combination of mATPase and MyHC (CMM) fibre-type categories were made: type I, I/IIA, IIA, IIA/IIX, IIX and miscellaneous (misc).

**Enzyme activity staining**

COX staining was performed by incubating sections for 1 h in a 50 mM Tris/HCl buffer (pH 7.6) containing 0.22 M sucrose, 14 mM 3,3’-diaminobenzidine tetrahydrochloride, 80 μM cytochrome c and 1300 U catalase. Sites of COX activity were coloured brown [24]. SDH staining was performed by incubating sections for 1 h at 37°C in a 0.2 M sodium phosphate buffer containing 0.1 M succinic acid and 1.2 mM nitro-blue tetrazolium. Sites of SDH activity were coloured blue [25]. GlyP staining was performed by incubating sections for 5 min in a 43 mM sodium acetate buffer (pH 5.6) containing 7 mM glucose-1-phosphate, 1 mM adenosine monophosphate (AMP), 0.01% glycogen and 15% ethanol [25], after which the newly formed polysaccharide was coloured blue with Lugol’s iodine. COX and SDH cross-sections were dehydrated in an ethanol range and mounted in Entallan®, GlyP sections were mounted in aqueous glycerin/gelatine that had been coloured with Lugol’s iodine. Within each section, three staining intensities were chosen reflecting fibre enzyme activity: positive (+), negative (-) or intermediate (±). For example, a fibre positive for COX, intermediate for SDH and negative for GlyP would be COX⁺, SDH⁻ and GlyP⁻. Figure 1g–i show examples of enzyme activity staining.

**Statistical analysis**

Values are reported as mean±standard deviation (sd) and error bars in figures reflect standard error of the mean (SEM). Intergroup data were compared using an unpaired t-test (corrected for unequal variances if appropriate) or one-way analysis of variance (ANOVA) (with unpaired t-test as post hoc test).

**Table 2. – Fibre-type classification**

<table>
<thead>
<tr>
<th>CMM fibre type</th>
<th>mATPase</th>
<th>MyHC</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>pH 4.4</td>
<td>pH 10.4</td>
<td>Double</td>
</tr>
<tr>
<td>I</td>
<td>++</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>I/IIA</td>
<td>+ +</td>
<td>+ or ++</td>
<td>++</td>
</tr>
<tr>
<td>IIA</td>
<td>-</td>
<td>++</td>
<td>-</td>
</tr>
<tr>
<td>IIA/IIX</td>
<td>- or +</td>
<td>++</td>
<td>+ or ++</td>
</tr>
<tr>
<td>IIX</td>
<td>+</td>
<td>++</td>
<td>or ++</td>
</tr>
<tr>
<td>Misc</td>
<td>+</td>
<td>++</td>
<td>or ++</td>
</tr>
</tbody>
</table>

Fibres were classified first on the basis of myofibrillar adenosine triphosphatase (mATPase) staining intensities (-, + or ++) and further classified by immunoreactivity (- or +). MyHC: myosin heavy chain; CMM: the combination of mATPase and MyHC fibre-type categories.

**Results**

Fifteen COPD patients (12 males and three females) and fifteen healthy controls (13 males and two females) participated in this study (table 1). There were no differences in sex or age between the groups. The body mass index (BMI), PəO₂, FEV₁ and the DL,CO were significantly lower, whereas the RV and the ITGV were higher in patients than in controls. Eight patients (with HRCT scores >30) were assigned to Emph⁺ and seven patients (with HRCT scores <30) to the Emph⁻ subgroup. The PəO₂, FEV₁ and the DL,CO were lower and the RV and the ITGV were higher for the Emph⁺ than for the Emph⁻ COPD subtype.

A typical example of histochemical results is shown in figure 1. First the data was interpreted as if based purely on mATPase staining (fig. 2a). The proportion of mATPase type-I fibres was lower (19% versus...
43%, p<0.001) and the proportion of mATPase type-IIx fibres was higher (46% versus 27%, p=0.004) in the COPD group compared to controls. There was no difference in the percentage of mATPase type-IIa fibres. By combining the three mATPase pre-incubation protocols with immunohistochemistry, five fibre-type categories were defined: CMM type I, IIA, IIX, I/IIA and I/IIA/IIx fibres, the latter two representing hybrid fibres (table 2). Fibre-type distribution was subsequently re-established with this more accurate method (fig. 2b). Again, the proportion of type-I fibres was lower (16.1% versus 42.4%, p<0.001) and the percentage of type-IIx fibres tended to be higher (23.8% versus 14.7%, p=0.088) in COPD than in controls. In addition, the proportion of hybrid-fibres I/IIA (5.9% versus 1.3%, p=0.044), I/IIA/IIx (22.9% versus 14.4%, p=0.041), and total (IIA+IIx/IIA) (28.8% versus 15.7%, p=0.008) were higher in COPD compared to healthy subjects. Fibres that did not fit into one of the categories discussed earlier were assigned to the miscellaneous group. Although the percentage of these fibres was also higher in COPD than in controls (1.6% versus 0.2%, p=0.017), their overall contribution to fibre-type composition was negligible. There was no difference in the percentage of type-IIa fibres between both groups.

Figure 3 shows the results of enzyme activity staining of COX-, SDH+ and GlyP-. Overall, the proportion of COX+ and SDH+ fibres was lower (20.1% versus 45.8%, p<0.001 and 14.2% versus 36.3%, p<0.001), whereas the proportion of COX- and SDH- fibres was higher (35.3% versus 23.8%, p=0.003 and 47.9% versus 25.0%, p<0.001, data not shown) in COPD than in the control group. The percentage of COX± fibres was also higher in COPD than in controls (44.6% versus 30.3%, p=0.002, data not shown). There were no differences in the proportion of GlyP+, GlyP-, GlyP± and SDH± fibres between patients and controls. The proportion of GlyP+ fibres in patients not treated with glucocorticosteroids (45.8%) was higher than in controls (34.2%, p=0.045) and also higher than in patients who did receive glucocorticosteroids (29.2%, p=0.017). Since enzyme activity staining and fibre-type characterization were performed on serial cross-sections, enzyme activity could be evaluated within fibre-type categories. In the CMM fibre-type categories IIA and IIA COPD patients had a lower proportion of fibres positive for the oxidative enzymes, as shown for COX+ and SDH+ (table 3). In CMM fibre-type I/IIA the proportion of COX± fibres was higher for patients (data not shown).

Within COPD there was a more pronounced decrease in the percentage of CMM type-I fibres in Emph+ than in Emph- (10.0% versus 23.1%, p=0.045) compared to controls (fig. 4). In each group at least one patient with no CMM type-I fibres at all, was found. No differences between the two subtypes were observed with respect to enzyme activity staining. Strong relationships were found for COPD between the proportion of CMM type-I fibres and the proportions of COX+ (r=0.77, p=0.001) and SDH+ (r=0.84, p<0.001) fibres (fig. 5). A positive relationship between age and the percentage of type-I fibres in healthy controls (r=0.61; p=0.015) was also observed. This relationship was also seen in the Emph- COPD subtype, although this did not reach statistical significance.

### Table 3 – Proportions of cytochrome c oxidase (COX+) and succinate dehydrogenase (SDH+) fibres within the combination of myofibrillar adenosine triphosphatase and myosin heavy chain fibre type categories

<table>
<thead>
<tr>
<th>Fibre type</th>
<th>COX+ fibres %</th>
<th>SDH+ fibres %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>COPD</td>
<td>Controls</td>
</tr>
<tr>
<td>I</td>
<td>87.8</td>
<td>82.7</td>
</tr>
<tr>
<td>I/IIA</td>
<td>73.3</td>
<td>33.3*</td>
</tr>
<tr>
<td>IIa/IIx</td>
<td>34.1</td>
<td>7.8**</td>
</tr>
<tr>
<td>IIa/IIx/IIx</td>
<td>2.5</td>
<td>2.4</td>
</tr>
<tr>
<td>I</td>
<td>0</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Significance of difference compared to controls. *: p<0.05; **: p<0.01; ***: p<0.001.

---

**Fig. 3.** Enzyme activity staining in the vastus lateralis. COX: cytochrome c oxidase; SDH: succinate dehydrogenase; GlyP: glycogen phosphorylase. □: controls; ■: chronic obstructive disease (COPD) patients. Significance of difference between the groups: **: p<0.01; ***: p<0.001.

**Fig. 4.** Combination of myofibrillar adenosine triphosphatase and myosin heavy chain fibre type-I proportion in chronic obstructive pulmonary disease subgroups. Emph-: non-emphysema; Emph+: emphysema. Significance of difference between the groups: *: p<0.05; **: p<0.01.
The proportion of COX fibres absent in Emph was found. The proportion of COX fibres and oxidative capacity in chronic obstructive pulmonary disease patients. The relationship was absent in Emph+ (r=0.49; p=0.290). No correlations between fibre-type proportions and lung function data were found. The proportion of COX+ fibres positively correlated with the $P_{a,O_2}$ (r=0.60, p=0.019).

Discussion

This study strongly suggests that the I to IIX fibre-type redistribution in the vastus lateralis of COPD patients occurs through gradual shifts in intracellular MyHC isoform content. Accordingly, the proportions of fibres with high activities of enzymes involved in oxidative energy metabolism are reduced in patients. These proportions are closely related to the proportion of type-I fibres, but even within IIA fibres oxidative capacity is reduced in COPD. There were no differences in glycolytic capacity between patients and controls. Furthermore, for the first time, it was shown that the low fibre type-I proportion is aggravated in patients with emphysema compared to COPD patients without emphysema.

In the present study, individual fibres were identified on the basis of a combination of three different mATPase staining techniques and immunohistochemistry. By doing this, the accurate distinction of type I, IIA and IIX fibres, but also I/IIA and IIA/IIX hybrid fibres could be made. Hybrid fibres contain multiple MyHC isoforms, which can co-exist in any ratio. In the present study, fibres were identified as being hybrid only if indicated by mATPase staining and immunohistochemistry. The higher percentage of hybrid fibres in COPD strongly suggests that gradual transformation of one fibre type into another takes place: I→I/IIA→IIA→IIA/IIX→IIX.

Unlike the mATPase type-IIX fibre-type proportion, the difference in CMM fibre type-IIX proportion between COPD patients and controls did not reach statistical significance. This can be explained by the fact that part of the mATPase IIX fibres are now assigned to the hybrid IIA/IIX fibre-type category. Compared to healthy subjects, a reduced proportion of mATPase type-I fibres and an increased percentage of mATPase type-II (IIA and/or IIX) fibres have been previously reported in COPD [4–6]. However, large variations in fibre-type distribution exist between these studies. Differences in disease severity and study populations may explain these differences in part, but the large diversity in applied histochemical techniques is also a contributing factor. In addition, hybrid fibres were formerly not often detected and therefore misclassified. For example, hybrid II/A fibres stain intermediate for mATPase activity after pre-incubation at pH 4.4 and will be identified as IIX fibres.

In this study, the proportions of COX+ and SDH+ fibres were reduced in the COPD group compared to controls, while the percentages of COX- and SDH-fibres were increased. Although enzyme activity staining is a semiquantitative method, it provides useful information with respect to localization. Accordingly, in muscle biopsy specimens, reduced activities of the mitochondrial enzymes citrate synthase, SDH and hydroxyacyl-coenzymeA dehydrogenase have been reported in COPD [7, 8]. The present data are not consistent with the outcome of the study performed by SAULEDA et al. [9], who found an increased COX activity and a negative correlation between COX activity and the $P_{a,O_2}$ for COPD patients. Since COX is involved in oxidative phosphorylation and it is the final enzyme of the respiratory chain interacting with oxygen, the authors have previously suggested that its increased activity may enhance the efficiency of residual oxygen extraction as an adaptation to hypoxia [3]. In contrast, a decrease in the percentage of COX+ fibres and a positive correlation between the proportion of COX+ fibres and the $P_{a,O_2}$ was observed in this study. Various explanations can be offered for the discrepancy between this data and previously published reports [9]. First, a point of consideration is that the mean $P_{a,O_2}$ in this patient group was not as low as the $P_{a,O_2}$ found by SAULEDA et al. [9] (9.9 kPa versus 8.3 kPa respectively). If hypoxia could upregulate COX activity, this would imply that the COX activity in the patient group in this study is lower than the COX activity in the COPD group observed by SAULEDA et al. [9]. Second, one could also argue that despite the reduced proportion of COX+ fibres, overall COX activity is elevated due to the observed increased proportion of COX± fibres in patients. However, overall staining intensity for COX was certainly not higher in COPD sections compared to controls. In addition, there was no relationship between the proportion of COX± fibres and the $P_{a,O_2}$. More research is needed to clarify the behaviour of COX in skeletal muscle of COPD.

One study described increased glycolytic enzyme activity phosphofructokinase (PFK) in the vastus lateralis of COPD patients [8]. In addition, increased PFK activity has been reported in lung transplant recipients compared to controls, although GlyP activity was found to be unchanged [27]. Correspondingly, an increased percentage of GlyP+ fibres was not
found in this study. An explanation for the unchanged GlyP+ fibre proportion in the present study is that seven from the 15 COPD patients received low doses of oral glucocorticosteroids. The proportion of GlyP+ fibres in patients not receiving corticosteroids was higher than in controls, suggesting that corticosteroids adversely affect GlyP activity. However, patients frequently suffering from exacerbations are more likely to receive corticosteroids and therefore systemic inflammation may be involved as well. The effect of glucocorticosteroids on glycolytic metabolism needs to be further elucidated.

In COPD patients in this study, the proportion of fibres that stained positive for COX and SDH declined in the same order of magnitude as the percentage of type-I fibres. In fact, the majority of the COX− and SDH+ fibres were classified as type-I fibres, which is underscored by the strong correlation between their proportions. Thus overall, the relative loss of type-I fibres and the loss of oxidative enzyme activity are linked. It has never been established before that the decline in both percentages of fibre type I and the activity of enzymes involved in oxidative energy metabolism in COPD are linked. Since enzyme activity staining and fibre-type classification in this study were performed on serial cross-sections, it was not only possible to examine the relationships between the fibre-type redistribution and enzyme activity, but also enzyme activities within the fibre-type categories.

The proportion of COX+ and SDH+ fibres within each of the individual CMM fibre types, I/IIA and IIA, were significantly lower for COPD compared to controls (table 3). In addition, the proportion of COX− fibres was higher in CMM type-IIA fibres of patients. It is therefore feasible that COX+ fibres transformed into COX− fibres. It is possible that this extra loss of oxidative capacity is specific for type-IIA fibres. Another possibility is that the loss of oxidative enzyme activity occurs in an early stage of fibre-type transition. It is feasible that as a result of the disease (i.e. hypoxia), oxidative energy metabolism is disturbed and the activities of the enzymes involved are reduced. Type-I and IIA fibres strongly depend on aerobic metabolism, whereas in type-II fibres energy conversion is based mainly on anaerobic, glycolytic metabolism. It is therefore tempting to state that in type-I fibres the co-expression of the MyHC-IIA isoform and that in type-II fibres the co-expression of the MyHC-IIX isoform is an adaptation to impaired oxidative energy metabolism. Alternatively, it is possible that either the reduced oxidative capacity is secondary to the changes in MyHC-isoform contents or that one or more common factors affect both oxidative capacity and MyHC-isoform contents simultaneously.

The present results indicate that the low fibre type-I proportion in COPD is more pronounced in Emph+ patients (stratified by HRCT) compared to Emph- patients. Like others the authors found a positive relationship between fibre type-I proportion and age in healthy subjects [28–30]. Due to the relative loss of type-I fibres this relationship is disturbed in COPD patients, being totally absent in the Emph+. The proportion of COX+ fibres was also lower in Emph+, but not statistically significant. A positive correlation between the PaO2 and the percentage of type-I fibres has been reported previously [5, 6]. In addition, a positive relationship between the MyHC-I content, and the DLco, and the FEV1, has been shown [10, 11]. However, in the present study these relationships between fibre-type proportions and lung function data were not observed, suggesting that fibre type-I proportion is not related to disease severity per se. COPD patients with a DLco <55% predicted are likely to desaturate during exercise [31]. Since the DLco is lower in the Emph+ patients, it can be speculated that chronic and especially intermittent hypoxia is directly or indirectly involved in causing the lower fibre type-I proportion compared to Emph- patients. This issue requires further investigation.

At this point, it is not completely understood which factors are causing the muscular abnormalities in COPD. Hypoxia has already been discussed earlier. However, oxidative stress may also play a role in the loss of mitochondrial enzyme activity and relative loss of type-I fibres, since it has been demonstrated that mitochondrial proteins are highly susceptible to oxidative damage [32]. The possible role of malnutrition is demonstrated by animal studies in which nutritional deprivation caused depressed muscular mitochondrial capacity [33–35]. Physical inactivity or disuse of limb muscles are potential contributors to the observed fibre-type shift [36]. However, the authors have not observed previously any difference between the daily physical activity levels of Emph+ and Emph− patients [37], while differences in fibre type-I proportions between these subgroups have now been found. In addition, none of the patients in this study was bedridden and it is therefore unlikely that disuse alone caused the very low fibre type-I proportions that were observed.

To conclude, this study demonstrates the involvement of increased proportions of hybrid I/IIA and IIA/IIX fibre types in the fibre-type shift from I to IIX in the vastus lateralis of chronic obstructive pulmonary disease patients compared to controls. The abnormal fibre type-I proportion is aggravated in emphysema patients. In addition, the percentage of fibres with high oxidative enzyme activities were also reduced in chronic obstructive pulmonary disease patients, being closely linked to the reduced fibre type-I proportion. Moreover, despite comparable IIA fibre-type proportions between patients and controls, oxidative capacity is reduced in this fibre type in patients. Further research should be carried out to identify the factors involved and the mechanisms underlying the muscular alterations in order to evaluate current treatment approaches and to develop new approaches.

Acknowledgements. The authors would like to thank A.F.M. Moorman for providing the antibodies against MyHC isoforms I, IIA and IIA+IIX.
References


12. ATS. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225–244.


33. Sieck GC, Lewis MJ, Blanco CE. Effects of undernutrition on diaphragm fiber size, SDH activity,


